Sensorion SA (EPA:ALSEN)
France · Delayed Price · Currency is EUR 6.61
-0.53 (-7.38%)
Oct 2, 2026, 5:35 PM CET
Sensorion Earnings Call Transcripts
Fiscal Year 2026
-
SENS-601, a gene therapy for GJB2-related hearing loss, has entered clinical development with first patient dosing targeted for early 2027. Supported by strong preclinical data and fast-track approval in France, the trial focuses on early intervention, binaural hearing restoration, and key endpoints of safety, tolerability, and hearing improvement.
Fiscal Year 2025
-
Sensorion is advancing gene therapies for hearing loss, with SENS-501 in Phase 1/2 showing early safety and behavioral improvements, and GJB2 progressing toward clinical trials. Strategic partnerships, a robust natural history network, and a focus on young patients differentiate its approach.